LOXO-RET-17001: A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)

March 06, 2019
https://clinicaltrials.gov/ct2/results?id=NCT03157128
Solid Tumors
Principal Investigator: Ding Wang, MD
Advanced solid tumors, RET fusion-positive, medullary thyroid cancer, RET activation
Accepting Participants